Academic Journal
Liposomal amphotericin B as an antifungal prophylaxis in bilateral lung transplantation: a safety analysis.
| Τίτλος: | Liposomal amphotericin B as an antifungal prophylaxis in bilateral lung transplantation: a safety analysis. |
|---|---|
| Συγγραφείς: | Boscolo A; Department of Medicine - DIMED, Section of Anaesthesiology and Intensive Care, University of Padova, 13, Vincenzo Gallucci Street, Padova, PD, 35125, Italy.; Institute of Anaesthesia and Intensive Care, Padova University Hospital, Padova, Italy., Sella N; Department of Medicine - DIMED, Section of Anaesthesiology and Intensive Care, University of Padova, 13, Vincenzo Gallucci Street, Padova, PD, 35125, Italy.; Institute of Anaesthesia and Intensive Care, Padova University Hospital, Padova, Italy., Congedi S; Department of Medicine - DIMED, Section of Anaesthesiology and Intensive Care, University of Padova, 13, Vincenzo Gallucci Street, Padova, PD, 35125, Italy., Paiusco I; Department of Medicine - DIMED, Section of Anaesthesiology and Intensive Care, University of Padova, 13, Vincenzo Gallucci Street, Padova, PD, 35125, Italy., Pistollato E; Institute of Anaesthesia and Intensive Care, Padova University Hospital, Padova, Italy., Zanaga A; Department of Medicine - DIMED, Section of Anaesthesiology and Intensive Care, University of Padova, 13, Vincenzo Gallucci Street, Padova, PD, 35125, Italy., Chiapperini F; Department of Medicine - DIMED, Section of Anaesthesiology and Intensive Care, University of Padova, 13, Vincenzo Gallucci Street, Padova, PD, 35125, Italy., Zarantonello F; Institute of Anaesthesia and Intensive Care, Padova University Hospital, Padova, Italy., Mormando G; Department of Medicine - DIMED, University of Padova, Padova, Italy., Pagliarini G; Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy., De Cassai A; Department of Medicine - DIMED, Section of Anaesthesiology and Intensive Care, University of Padova, 13, Vincenzo Gallucci Street, Padova, PD, 35125, Italy.; Institute of Anaesthesia and Intensive Care, Padova University Hospital, Padova, Italy., Pettenuzzo T; Department of Medicine - DIMED, Section of Anaesthesiology and Intensive Care, University of Padova, 13, Vincenzo Gallucci Street, Padova, PD, 35125, Italy. tommaso.pettenuzzo@unipd.it.; Institute of Anaesthesia and Intensive Care, Padova University Hospital, Padova, Italy. tommaso.pettenuzzo@unipd.it., Dell'Amore A; Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy., Navalesi P; Department of Medicine - DIMED, Section of Anaesthesiology and Intensive Care, University of Padova, 13, Vincenzo Gallucci Street, Padova, PD, 35125, Italy.; Institute of Anaesthesia and Intensive Care, Padova University Hospital, Padova, Italy. |
| Πηγή: | BMC pharmacology & toxicology [BMC Pharmacol Toxicol] 2026 Aug 03; Vol. 27 (1). Date of Electronic Publication: 2026 Aug 03. |
| Τύπος έκδοσης: | Journal Article; Observational Study |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: BioMed Central Country of Publication: England NLM ID: 101590449 Publication Model: Electronic Cited Medium: Internet ISSN: 2050-6511 (Electronic) Linking ISSN: 20506511 NLM ISO Abbreviation: BMC Pharmacol Toxicol Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: London : BioMed Central |
| Ιατρικοί όροι (MeSH): | Amphotericin B*/adverse effects , Amphotericin B*/therapeutic use , Antifungal Agents*/adverse effects , Antifungal Agents*/therapeutic use , Mycoses*/prevention & control , Lung Transplantation*, Acute Kidney Injury/chemically induced ; Humans ; Female ; Retrospective Studies ; Male ; Middle Aged ; Adult ; Aged |
| Περίληψη: | Background: Lung transplantation (LT) is the definitive treatment for end-stage chronic respiratory failure. Despite improvements in surgical and perioperative care, fungal infections remain a major complication in LT recipients, and antifungal prophylaxis with liposomal amphotericin B (L-AmB) is commonly used. However, evidence on the safety of L-AmB administration in LT recipients remains limited. This retrospective observational study aimed to assess the profile of renal, hepatic and hematologic safety, and the incidence of hypersensitivity adverse events following prophylactic L-AmB use in LT recipients. Methods: A retrospective, single-center observational study of adult patients (≥ 18 years) who underwent their first bilateral LT at the University Hospital of Padua (Italy), between January 2020 and March 2025. All patients received intravenous L-AmB (3 mg/kg/day for 5 days) as postoperative antifungal prophylaxis. Adverse effects were assessed based on acute kidney injury (AKI), liver toxicity, hematotoxicity, and infusion reactions. Laboratory values were collected at baseline, on days 1, 2, 3, 7, and 14 post-L-AmB initiation. Results: 189 LT recipients were screened and 140 enrolled. Concerning safety profile, AKI occurred in 55 (39%) patients, with serum creatinine peaking at 48 h (p = 0.025), as compared to baseline. Mild transaminase elevations occurred in 86% of patients within the first 48 h, and bilirubin increased in 10%, with no episodes of acute liver failure. Anemia (85%) and transient thrombocytopenia (9%) were observed. Hypokalemia was found in 28%. Renal replacement therapy was needed in 2%. No infusion-related or allergic reactions to L-AmB were observed. According to the institutional fungal surveillance protocol, no proven, probable, or possible invasive fungal infections were documented during the observation period. However, the present study was not designed to assess the prophylactic efficacy of L-AmB. Conclusions: In this cohort of bilateral LT recipients receiving standardized L-AmB prophylaxis, no discontinuation, dose adjustment, infusion reaction, or proven fungal infection was documented. Renal, hepatic, hematologic, and electrolyte abnormalities were frequent; but cannot be specifically attributed to L-AmB in the absence of a comparator group, given the multifactorial pathophysiology of the early post-transplant period. These findings underscore the importance of vigilant monitoring of organ function during L-AmB administration in this vulnerable population. (© 2026. The Author(s).) |
| Competing Interests: | Declarations. Ethics approval and consent to participate: We confirm that all methods were carried out in accordance with relevant guidelines and regulations of the Helsinki declaration. Informed consent was obtained from all subjects. This study was approved by the Institutional Ethics Committee of Padua University Hospital (reference number: 6320/AO/25, 05/15/2025). Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. |
| References: | Cell Physiol Biochem. 2009;24(3-4):263-70. (PMID: 19710541) Ann Transl Med. 2020 Mar;8(6):414. (PMID: 32355858) Int J Antimicrob Agents. 2011 Nov;38(5):417-20. (PMID: 21885259) Cochrane Database Syst Rev. 2015 Nov 23;(11):CD010481. (PMID: 26595825) Mycoses. 2015 Feb;58(2):104-12. (PMID: 25590436) Infect Dis (Lond). 2016 Feb;48(2):161-6. (PMID: 26513601) AIDS Res Ther. 2024 Sep 29;21(1):66. (PMID: 39343879) Antimicrob Agents Chemother. 2025 Mar 05;69(3):e0169224. (PMID: 39882912) Saudi J Anaesth. 2019 Apr;13(Suppl 1):S31-S34. (PMID: 30930717) J Control Release. 2015 Aug 10;211:10-21. (PMID: 26047758) BMJ Case Rep. 2020 May 12;13(5):. (PMID: 32404321) Expert Opin Drug Saf. 2013 Nov;12(6):881-95. (PMID: 23931455) Antimicrob Agents Chemother. 1978 Aug;14(2):270-3. (PMID: 697352) Future Microbiol. 2012 May;7(5):639-55. (PMID: 22568718) Mycoses. 2024 Aug;67(8):e13779. (PMID: 39101705) J Oncol Pharm Pract. 2024 Jul;30(5):919-929. (PMID: 38720564) J Heart Lung Transplant. 2021 Nov;40(11):1327-1348. (PMID: 34732281) Expert Opin Drug Saf. 2021 Sep;20(9):1061-1074. (PMID: 33896310) J Heart Lung Transplant. 2016 Oct;35(10):1149-1157. (PMID: 27772667) Antibiotics (Basel). 2024 Aug 12;13(8):. (PMID: 39200060) Clin Infect Dis. 2019 May 2;68(Suppl 4):S244-S259. (PMID: 31222254) Appl Microbiol Biotechnol. 2005 Aug;68(2):151-62. (PMID: 15821914) Adv Chronic Kidney Dis. 2009 Jul;16(4):256-67. (PMID: 19576556) J Clin Med. 2019 Oct 17;8(10):. (PMID: 31627379) Kidney Int. 1992 Jun;41(6):1588-94. (PMID: 1501413) Mol Pharm. 2024 Nov 4;21(11):5392-5412. (PMID: 39373243) Infect Dis Ther. 2025 Jan;14(1):133-148. (PMID: 39615018) PLoS Negl Trop Dis. 2014 Jun 12;8(6):e2864. (PMID: 24922279) J Med Toxicol. 2011 Mar;7(1):12-5. (PMID: 21057910) Anesthesiology. 2022 Mar 1;136(3):482-499. (PMID: 34910811) J Infect Chemother. 2021 Feb;27(2):277-283. (PMID: 33109439) Expert Opin Drug Saf. 2017 Feb;16(2):149-165. (PMID: 27927037) J Infect Chemother. 2024 Aug;30(8):741-745. (PMID: 38354908) Mycoses. 2024 Jul;67(7):e13771. (PMID: 39031945) Clin Ther. 2003 May;25(5):1295-320. (PMID: 12867214) Leuk Lymphoma. 2015;56(10):2889-94. (PMID: 25629990) Transplantation. 2021 Dec 1;105(12):2538-2545. (PMID: 33982907) Methodist Debakey Cardiovasc J. 2022 Sep 06;18(4):34-40. (PMID: 36132582) Transplant Rev (Orlando). 2019 Apr;33(2):77-86. (PMID: 30579665) J Heart Lung Transplant. 2014 Oct;33(10):1009-24. (PMID: 25242125) J Fungi (Basel). 2024 Jan 19;10(1):. (PMID: 38276026) Eur J Intern Med. 2022 Mar;97:26-31. (PMID: 34772600) Diagn Microbiol Infect Dis. 2013 Jul;76(3):361-7. (PMID: 23774005) |
| Contributed Indexing: | Keywords: Antifungal prophylaxis; Liposomal amphotericin B; Lung transplantation; Safety; Toxicity |
| Substance Nomenclature: | 7XU7A7DROE (Amphotericin B) 0 (Antifungal Agents) 0 (liposomal amphotericin B) |
| Entry Date(s): | Date Created: 20260912 Date Completed: 20260913 Latest Revision: 20260922 |
| Update Code: | 20260923 |
| PubMed Central ID: | PMC13571325 |
| DOI: | 10.1186/s40360-026-01189-x |
| PMID: | 42732067 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 2050-6511 |
|---|---|
| DOI: | 10.1186/s40360-026-01189-x |